Start Date: 3/11/2002 7:00 AM
End Date: 3/11/2002 3:00 PM
The Industry Liaison Group met with members of the Pharmacogenetics Research Network on the evening of March 11, 2002 at Stanford University. At their meeting, the group considered the newest release of PharmGKB (available at http://www.pharmgkb.org), and discussed the “levels of evidence” model for relating phenotype to genotype information as four categories: molecular and cellular assays, pharmacokinetics, pharmacodynamics, and clinical outcomes.
There was also a discussion of the current terminology used to categorize samples derived from clinical pharmacogenetic studies, including areas where standards are not yet set. Additionally, the joint group considered the issues underlying communication of the importance of pharmacogenetics to the public and the press, and the distinction between research studies and current medical practice. They agreed that this is a challenging area, where the network's goal is to educate and yet not endorse.
The meeting included informal exchanges around the topic of scientific opportunities in the field for academia and for industry. The evening concluded with the attendees looking forward to attending the public meeting the next day, March 12th, in Fairchild Auditorium at Stanford University. A summary of the presentations at that day's meeting can be found at http://archive.nigms.nih.gov/pharmacogenetics/2002meeting_report.pdf.
Donald C. Anderson, M.D. Pharmacia Corporation 7000 Portage Road 7272-24-113 Kalamazoo, Michigan 49001-0199
Wayne H. Anderson, Ph.D.* GlaxoSmithKline Building 5, Room 5808 P.O. Box 13398 Research Triangle Park, North Carolina 27709
Lee E. Babiss, Ph.D. ** Hoffmann-La Roche Inc. Preclinical Research and Development 340 Kingsland Street Nutley, New Jersey 07110
Andrew Joseph Dorner, Ph.D.*,** Wyeth Research 2 Burtt Road Andover, Massachusetts 01810
Daniel Farkas, Ph.D.*, ** Motorola Life Sciences 757 South Raymond Avenue Pasadena, California 91105
Larry Gelbert, Ph.D.*, ** Research Scientist Research Technologies and Proteins Eli Lilly and Company DC 0444 Lilly Corporate Center Indianapolis, Indiana 46285
Penelope K. Manasco, M.D** First Genetic Trust Three Parkway North Center Deerfield, IL 60015
Glenn A. Miller, Ph.D.* Genzyme Corporation 1 Mountain Road Framingham, Massachusetts 01701
Brian B. Spear, Ph.D. Abbott Laboratories Department 424, AP6A-1 100 Abbott Park Road Abbott Park, Illinois 60064-6008
Vincent P. Stanton, Jr., M.D. Variagenics, Inc. 60 Hampshire Street Cambridge, Massachusetts 02139
Rochelle M. Long, Ph.D. National Institute of General Medical Sciences National Institutes of Health Natcher Building, Room 2AS.49G 45 Center Drive MSC 6200 Bethesda, Maryland 20892-6200 Tel: (301) 594-3827 Fax: (301) 480-2802 Email: rochelle_long@nih.gov
Gillian R. Woollett, M.A., D.Phil. Pharmaceutical Research and Manufacturers of America 110 Fifteenth Street, NW Washington, D.C. 20005
* New members in 2002
** Not in attendance
6:00 p.m. — Dinner
7:00 p.m. — Welcome on behalf of NIH Rochelle Long
7:15 p.m. — Review of Recommendations from January 11, 2001 Meeting Rochelle Long and Mark Ratain
7:30 p.m. — PharmGKB: Status and Opportunities Russ Altman
8:00 p.m. — Potential Areas of Collaboration: Human Subjects Issues and Nomenclature Brian Spear and Scott Weiss
8:30 p.m. — Communications with the Public: Collaborations Between Industry and Network Kathy Giacomini and Alison Davis
9:00 p.m. — Other Potential Areas of Collaboration (General Discussion) Howard McLeod and Vince Stanton
9:30 p.m. — Adjourn
